SEC Form 4 · accession 0002064832-26-000314
Perspective Therapeutics, Inc. · CATX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lantheus Alpha Therapy, LLC
10% Owner
Period of report
Aug 31, 2026
Accepted (ET)
Sep 4, 2026 · 4:58 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000728387
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F5 | Aug 31, 2026 | S | 78,145 | $3.143 | D | 11,599,194 | D | |
| Common StockF1,F2,F4,F5 | Sep 1, 2026 | S | 35,769 | $3.1193 | D | 11,563,425 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.
- F2These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- F5Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.